Pancreaticobiliary Neoplasm

Case study of a 46-year old male patient with Peutz-Jeghers Syndrome and pancreatic cancer. A germline STK11 D194E mutation was identified with LOH in the tumor sample. phospho-S6 ribosomal protein st… (full text at CIViC)

PMID 21189378 · Klümpen et al., 2011 · Open in CIViC

In a preclinical study using STK11/LKB1-deficient pancreatic ductal adenocarcinoma (PDAC) cell lines (TB 32047, PANC-1, SUIT2, SU86.86, KPC792) and C57BL/6 orthotopic mouse models (n = 5 per group), t… (full text at CIViC)

PMID 38461159 · Zhang et al., 2024 · Open in CIViC

Temozolomide (TMZ), the principal alkylating agent used in PanNET, drives acquisition of a hypermutator phenotype through direct mutagenesis. In a paired pre/post-TMZ cohort (23 patients), a hypermuta… (full text at CIViC)

PMID 41244370 · Taboada et al., 2025 · Open in CIViC

In a clinical study including 106 patients, over expression of TNC-L is significantly associated with decreased OS by a multivariate analysis (p = 0.0005).

PMID 31463696 · Hagiwara et al., 2020 · Open in CIViC

In an in vitro study, an increased gemcitabine IC50 significantly correlated with increased concentration of TNfnA-D (TNC-L). Resistance reached a platform at 20 ug/ml (p < 0.01).

PMID 20686216 · Gong et al., 2010 · Open in CIViC

In this retrospective analysis, tumor samples from 101 patients from the CONKO-001 trial, who received curatively intended surgery for pancreatic adenocarcinoma (PDAC) followed by adjuvant chemotherap… (full text at CIViC)

PMID 32234756 · Sinn et al., 2020 · Open in CIViC

Gene symbol publication providing minimal information. A VHL gene mutation at codon 111, AGC-ATC, Ser-Ile is associated to pancreatic cancer. It is unclear if this variant is somatic or germline. It i… (full text at CIViC)

PMID 10942118 · Bradley et al., 2000 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

A patient with pancreatic cancer harboring NTRK fusion was treated with larotrectinib. The best overall response was PR at 2 months but the tumor progressed after 6 months.

PMID 31605106 · O'Reilly et al., 2019 · Open in CIViC

In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, one patient with pancreatic cancer with NTRK fusion showed PR.

PMID 29466156 · Drilon et al., 2018 · Open in CIViC

In a Phase I/II study of Larotrectinib, highly selective TRK inhibitor, two patient with cholangiocarcinoma with NTRK fusion was enrolled. One of the two patient showed PR.